Chinese biotech startup Excalipoint has secured $69 million in funding to advance its portfolio of next-generation T cell engagers. The company is developing multifaceted antibodies that it believes represent advances over existing T cell engagement treatments.
According to BioPharma Dive, this funding round ranks as one of the largest of its kind for a China-based drug startup. The capital will support Excalipoint's pipeline of T cell engager therapies, though specific clinical trial details and development timelines were not disclosed in the available reporting.